3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
45
Endometrial Neoplasms
10
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Progesterone Resistance
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Endometrial Hyperplasia
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Obesity
1
Neoplasms by Site
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Infertility, Female
1
Infertility
1
Interventions
Letrozole
2
ribociclib
1
palbociclib
1
abemaciclib
1
Fulvestrant
1
Epirubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
HR+/HER2- Breast Cancer
×
Letrozole
×
Clear all
NCT07492641
2026-06-03
KANDELA-302
BeOne Medicines
Phase 3
Recruiting
1,056 enrolled
NCT06998407
2026-05-04
AVZO-023-1001
Avenzo Therapeutics, Inc.
Phase 1/2
Recruiting
380 enrolled